Back

Chinese biotech firms target $80 billion global GLP-1 market

Verifying
  • Chinese biotech companies are targeting the global GLP-1 medicines market.
  • The global GLP-1 market is valued at $80 billion.
  • Eli Lilly and Novo Nordisk lead the market with Mounjaro and Ozempic.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.